Innovent Receives China National Medical Products Administration Approval for Olverembatinib

Innovent Receives China National Medical Products Administration Approval for Olverembatinib

By, Admin 6 June 2023

Innovent Biologics announced that the Centre for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has awarded Breakthrough Therapy Designation (BTD) for olverembatinib. This designation recognises it as a potential promising treatment for patients diagnosed with succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumour (GIST) who have undergone first-line therapy. Olverembatinib is a novel third-generation BCR-ABL inhibitor that has received approval in China for the treatment of adult patients with tyrosine kinase inhibitor (TKI)-resistant chronic-phase chronic myeloid leukaemia (CML-CP) or accelerated-phase CML (CML-AP) that harbour the T315I mutation. Olverembatinib, an orally active third-generation BCR-ABL inhibitor has shown efficacy in targeting a range of BCR-ABL mutants, including the challenging T315I mutation commonly encountered in CML. By offering a therapeutic option for patients with these resistant forms of CML, olverembatinib represents a significant advancement in the field of leukaemia treatment.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!